Why the study?
Does rivaroxaban reduce the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk?
Does rivaroxaban reduce the risk of cognitive decline in individuals with atrial fibrillation and low thromboembolic risk?
Rivaroxaban does not appear to impact the risk of cognitive decline in patients with atrial fibrillation and low thromboembolic risk.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Proietti et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: